What is the current stock price of Hikma Pharmaceuticals PLC (HKMPF)?

As of the latest market data, Hikma Pharmaceuticals PLC (HKMPF) is trading at $18.72. The stock has seen a gain of 3.35% today.

Does Hikma Pharmaceuticals PLC (HKMPF) pay a dividend?

Based on current data, Hikma Pharmaceuticals PLC does not have a confirmed active dividend policy.

What is the market cap of Hikma Pharmaceuticals PLC?

The current market capitalization of Hikma Pharmaceuticals PLC (HKMPF) is approximately unavailable.

HKMPF

Hikma Pharmaceuticals PLC·Healthcare

18.72

3.352%(+0.61)

Market Closed

19.20

2.585%(+0.48)

After Hours

Last Updated: — ET

52W L: $16.3452W H: $27.96

HKMPF NEWS

seekingalpha.com

Feb 28

Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript

seekingalpha.com

Feb 26

Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript

proactiveinvestors.co.uk

Feb 26

Hikma Pharma tumbles on softer guidance as buyback fails to soften pill

Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026. Executive chair Said Darwazah will become full-time chief executive for the next two years, with current chief financial officer Khalid Nabilsi becoming deputy chief executive with responsibility for North America and Europe.

defenseworld.net

Feb 24

Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current

Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

9,500

IPO Date

2012-08-22

Beta

0.61

Websitewww.hikma.com↗